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Background: Hodgkin's lymphoma has high rates of cure, but in 15% to 20% of general patients and
between 35% and 40% of those in advanced stages, the disease will progress or will relapse after
initial treatment. For this group, hematopoietic stem cell transplantation is considered one option of
salvage therapy.
Objectives: To evaluate a group of 106 patients with Hodgkin's lymphoma, who suffered relapse or
who were refractory to treatment, submitted to autologous hematopoietic stem cell transplantation in
a single transplant center.
Methods: A retrospective study was performed with data collected from patient charts. The analysis
involved 106 classical Hodgkin's lymphoma patients who were consecutively submitted to high-dose
chemotherapy followed by autologous transplants in a single institution from April 1993 to December
2006.
Results: The overall survival rates of this population at five and ten years were 86% and 70%,
respectively. The disease-free survival was approximately 60% at five years. Four patients died of
procedure-related causes but relapse of classical Hodgkin's lymphoma after transplant was the most
frequent cause of death. Univariate analysis shows that sensitivity to pre-transplant treatment and
hemoglobin < 10 g/dL at diagnosis had an impact on patient survival. Unlike other studies, B-type
symptoms did not seem to affect overall survival. Lactic dehydrogenase and serum albumin
concentrations analyzed at diagnosis did not influence patient survival either.
Conclusion: Autologous hematopoietic stem cell transplantation is an effective treatment strategy for
early and late relapse in classical Hodgkin's lymphoma for cases that were responsive to pre-
transplant chemotherapy. Refractory to treatment is a sign of worse prognosis. Additionally, a
hemoglobin concentration below 10 g/dL at diagnosis of Hodgkin's lymphoma has a negative impact
on the survival of patients after transplant. As far as we know this relationship has not been previously
reported.
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Introduction
Classical Hodgkin's lymphoma (cHL) is a disease that has one of the highest cure
rates of all human cancers with long survival when patients are submitted to first-line
treatment protocols which involve multiple chemotherapeutic agents with or without
radiation such as the ABVD protocol. The ABVD protocol consists of four to six 28-day
cycles of doxorubicin 25 mg/m2, bleomycin 10 mg/m2, vinblastine 6 mg/m2 and dacarbazine
375 mg/m2 on days one and 15 of each cycle. The four drugs, administered intravenously,
have few immediate toxic effects.(1) More intense treatment protocols, such as escalated
BEACOPP, an association of bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine and prednisone, promote a higher initial remission rate and
increased disease-free survival in patients in advanced stages of disease. However the
toxic effects and treatment-related mortality are higher.(2) Early stages of the disease allow
treatment with few cycles of chemotherapy and low dose radiation, thereby minimizing
long-term side effects.(3) Despite the effectiveness of existing regimens, it has been reported
in the literature that about 20% of patients in early disease stage and 35% to 40% of
patients with advanced disease will have disease progression or relapse after the initial
treatment.(4) It is well known that these patients will not have good survival when treated
with conventional chemotherapy in particular those considered primary refractory patients
and that have early relapse, i.e. within 12 months of initial treatment.(5) In order to improve
treatment outcomes for this group of patients, autologous hematopoietic stem cell
transplantation (HSCT) has been used in refractory and relapsed cHL cases. Today there is
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ample documentation of the effectiveness of this approach(6)
particularly in two randomized studies, the British National
Lymphoma Investigation (BNLI)(7) and Germany's Lymphoma
Study Group (GHSG).(8)
Except for response to treatment of the disease prior to
HSCT, no other predictive factor was found with an impact
on survival in all the publications analyzed.(9) With data from
a single treatment center in Brazil, the objective of this study
was to evaluate patient survival and to identify possible
predictors of survival, major treatment-related toxic effects
and causes of death.
Methods
This is a retrospective study with data obtained from
patient charts. Analysis involved 106 patients with cHL who
were consecutively submitted to high-dose chemotherapy
followed by autologous HSCT in a single institution from
April 1993 to December 2006. Patients were followed up until
December 2007, i.e. twelve months after concluding enrolment
in the study; thus the mean follow up time was 47.5 months
(12-178 months). For all patients, the bone marrow had no
evidence of infiltration by cHL at HSCT as proven by
histopathological studies of samples obtained from at least
one posterior iliac crest.
After diagnosis patients were submitted to
conventional treatment protocols with the MOPP protocol
(six 28-day cycles of mechlorethamine 6 mg/m2, vincristine
1.4 mg/m2, procarbazine 100 mg/m2 on the first day and
prednisone 40 mg/m2 for five days on days one and eight of
each cycle), with ABVD or an association of both being used
in 97 patients (91.5%). Involved-field radiotherapy was used
as adjuvant treatment for 65% of patients with extensive
tumor mass ("bulky").
Complete remission was defined as the absence of tu-
mor for at least four weeks after the completion of chemotherapy
pre-HSCT while partial remission was defined as a reduction in
over 50% of the volume of the regions affected by the tumor
for at least four weeks after chemotherapy without the
appearance of new tumor-related lesions.
Patients were stratified as responders to treatment used
prior to HSCT when they attained a reduction of more than
50% of the initial tumor in the pre-transplant period (61.9% of
cases) and refractory for those who had less than 50% reduction
in tumor involvement in the pre-HSCT period (38.1%).
Of the responders, 54 patients were in second complete
remission (85%), four in second partial remission, four in
third complete remission and one in first partial remission.
Pre-HSCT high-dose salvage chemotherapy was performed
in 45 patients (42.4%) using regimens based on ifosfamide
with etoposide (53.33%), cytarabine with dexamethasone
(22.22%) and ifosfamide with gemcitabine (24.44%); 61
patients (57.54%) did not receive salvage chemotherapy. The
mobilization of hematopoietic stem cells was attained in 83
patients (78%) with cyclophosphamide 60 mg/kg on two
consecutive days followed by granulocyte colony stimulating
factor (G-CSF) at doses of 6 to 17 mcg/kg. For 25 patients
(22%), mobilization failed and collection was achieved by
multiple bone marrow aspirations. The resulting cells were
cryopreserved for use to rescue bone marrow function after
conditioning. The conditioning protocols used were BEAM
(BCNU 300 mg/m2 on D-1, cytarabine 400mg/m2 from D-2 to
D-5, etoposide 200 mg/m2 from D-2 to D-5 and melphalan
140 mg/m2 on D-6) in 55.38% of patients and CVB (BCNU
300 mg/m2 on D-7, etoposide 200 mg/m2 on D-6 to D-3 and
cyclophosphamide 60 mg/m2 on D-2 and D-1) in 27.35% of
patients. MVB (a regime that substituted cyclophosphamide
for melphalan at a dose of 140 mg/m2 on D-1) was used for
12.26% of the patients and 4.71% received other conditioning
regimens.
The World Health Organization toxicity grading scale,
graduated from 0 to 4(10) was used to study the toxic effects
of HSCT. The first day of two consecutive days with
leukocyte counts above 1 x 109 cells/L or granulocytes above
0.5 x 109 cells/L, or platelets greater than 20 x 109 cells/L
without transfusion within the previous seven days was
considered the time of bone marrow engraftment. Death that
occurred before D+100 after infusion of cryopreserved bone
marrow cells was considered transplant related. A CD34 cell
count by flow cytometry was used to quantify hematopoietic
precursor cells harvested and infused in the patient.
This study was approved by the Ethics Committee for
the Analysis of Research Projects (CAPPESQ) of the Hospital
of the Medicine School, Universidade de São Paulo (number
0332/09 and Resolution 196/96 of the National Health
Council). Survival was analyzed using the Kaplan-Meier
method(11) with multivariate analysis by the Cox model to
evaluate prognostic factors for survival. Statistical
significance was considered for a p-value < 0.05. Calculations
of percentages, means and medians were used when
necessary.
Results
Autologous HSCT for cHL accounted for about 7%
of 2067 indications for transplantation performed up to
December 2006 at Hospital das Clínicas and about 20% of all
autologous transplants in this period. The main characteristics
of this transplant population are listed in Table 1. The overall
survival rates of this population at five and ten years were
86% and 70%, respectively. The disease-free survival was
approximately 60% at five years.
 A median of 2.6 x 106 CD34+ cells per kg of body weight
was collected utilizing mobilization with a median time to
engrafting of 12 days. There was no difference in survival in
relation to the conditioning regimens employed (p=0.17). The
mobilization of hematopoietic precursor cells in peripheral
blood collection was unsuccessful for about a quarter of
patients, so for these harvesting was by bone marrow
aspiration.(12)
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Univariate analysis (Table 2) shows that sensitivity
to pre-HSCT treatment and hemoglobin < 10 g/dL at
diagnosis had an impact on patient survival. Unlike other
studies, B-type symptoms did not affect overall survival.
Lactic dehydrogenase and serum albumin concentrations
analyzed at diagnosis did not influence patient survival
either.
Four patients had died by D+100 after HSCT (3.74%).
The causes were severe systemic infection in three cases
and one case of bronchiolitis probably due to the use of a
chemotherapeutic agent.
Relapse of cHL after HSCT was the most frequent cause
of death. Of the 24 deaths after D+100, cHL as a cause, that
is, progression after ASCT, accounted for 13 cases (54%).
Septicemia was the cause of death in four patients (6.6%).
One patient died of acute myocardial infarction, one from
pneumonia, one by bleeding of the colon followed by
hypovolemic shock, one by systemic aspergillosis and one
had respiratory failure of undefined cause. In two cases the
exact cause of death was not identified. Myelodysplastic
syndrome (MDS), classified as multilineage dysplasia,
diagnosed two years after the HSCT, was considered a late
treatment-related complication of one patient who was still
alive at the end of the study period.
Fever was the most frequent complication in the first
100 days after HSCT, present in 91.5% of patients. Fever
without identified focus (38.7%), proven bacterial infection
(27.37%), catheter infection (11.3%), sepsis (6.6%), systemic
candidiasis (3.77%), aspergillosis (1.88%) and cytomegalovirus
infection (1.88%) were reported.
Discussion
Patients with cHL refractory to treatment and those
that suffer relapse are problematic; on comparing current
treatment strategies, autologous HSCT provides the best
results for these individuals. In this study, the overall survival
at five years was around 80% with evidence of low toxicity
and procedure-related mortality. Figure 1 shows the overall
survival curve after autologous HSCT of patients diagnosed
with cHL.
Today this group of patients can be treated, from a
practical standpoint, with conventional chemotherapy
followed by high dose chemotherapy and autologous or
allogeneic HSCT, as well as with experimental therapies, often
involving specific monoclonal antibodies and/or palliative
radiotherapy. High-dose chemotherapy gives different results
when applied to patients with minimal disease compared to
patients with extensive areas of tumor; survival at three years
ranges from 70% in the former group compared to only 15%
for patients of the latter.(13) Primary refractory cases and those
with early relapse, i.e. within 12 months of initial treatment,
do not respond well to conventional treatment;14 Bonadonna
et al. reported less than 15% of these patients had disease-
free survival at five years.(15)
The use of conventional salvage therapy achieved cure
rates of less than 20% in the various series of published
cases.(16) The results of this study showed that patients with
relapsed and refractory cHL benefit from autologous HSCT.
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In regard to prognostic factors, serum hemoglobin
concentrations below 10 g/dL at diagnosis had a negative
impact on survival; this has not been reported in any other
publications and should thus be confirmed in future studies
(Figure 2). The worse outcomes correlated with the presence
of B-type symptoms as reported by other authors was not
confirmed in our study. However, response to pre-transplant
chemotherapy was the main determinant of improved survival
after HSCT, as illustrated in Figure 3.
Refractory cases could benefit from a more intense initial
approach, as a more precise diagnosis can be attained today
through studies using positron emission tomography.(17,18)
Sureda et al., on analyzing 494 cHL patients submitted to HSCT
by the Spanish Lymphoma Study Group, also noted that
chemosensitivity is an important variable that determines
response to HSCT. These authors even suggested that
refractory patients should be treated more aggressively in
the early stages of treatment.(19) The group at Seattle's Fred
Hutchinson Cancer Research Center, in a study published in
2008 that analyzed 167 patients with refractory cHL submitted
to HSCT, failed to define any predictors of survival in this
group. They concluded, however, that HSCT can be
performed in refractory patients, but only one in three patients
will survive more than five years.(9)
Due to the high number of CD30 cells expressed in
cHL, this is considered a promising disease for targeted
monoclonal therapy with the use of anti-CD30 antibodies.
Some forms of humanized antibodies have been tested in
clinical trials but showed low response rates and caused
grade II and III pulmonary and hepatic toxicity and
suppression of bone marrow function when used as therapy
in isolation,(20) thus they give worse outcomes than HSCT.
Radiotherapy may be useful as adjuvant therapy in the
treatment of localized relapse, but without a complete cure
being expected. Lymphomas are malignant tumors  that are
highly sensitive to radiotherapy, especially cHL.(21) Allogeneic
Figure 1–  Overall survival of patients with classic Hodgkin's lymphoma
after autologous hematopoietic stem cell transplantation (n = 105)
Figure 2 – Hemoglobin less than 10 g/dL at diagnosis and survival after
hematopoietic stem cell transplantation (n = 105)
Figure 3 – Survival after hematopoietic stem cell transplantation
according to response to pre-transplant chemotherapy (n = 105)
transplants, even with reduced conditioning doses, should
be reserved for selected refractory cases and patients that
relapse after autologous transplants because the higher
mortality rate in cHL patients makes indication a difficult
decision.(22) Survival does not seem to be higher than in
autologous transplants due to the high rate of procedure-
related mortality, in spite of the biological graft-versus-
lymphoma effect.(23)
Conclusion
We believe that autologous HSCT is an effective
treatment strategy for early and late relapse in cHL cases
that are responsive to pre-HSCT chemotherapy, giving an
overall survival rate of greater than 80% at five years.
Patients are tolerant to the BEAM and CVB conditioning
regimens and in our series of patients the mortality rate
within one hundred days of HSCT was 3.74%. Patients who
are refractory to primary treatment do not exhibit the same
response as those who responded to pre-HSCT
chemotherapy, and thus refractory to treatment is a sign of
worse prognosis.
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The presence of hemoglobin concentrations below
10 g/dL at diagnosis of cHL is a negative impact factor on
the survival of patients after HSCT. We did not find any
mention of this relationship in the literature but according to
the sample in this study we believe that the hemoglobin level
at diagnosis may be a possible predictive factor of poor
prognosis, which should be taken into account when
indicating HSCT.
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